{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:24:42Z","timestamp":1789179882438,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11060-024-04711-5","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:01:51Z","timestamp":1715587311000},"page":"147-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing"],"prefix":"10.1007","volume":"169","author":[{"given":"Archis R.","family":"Bhandarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Bhandarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusica","family":"Babovic-Vuksanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"4711_CR1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13:834\u2013843","journal-title":"Lancet Neurol"},{"key":"4711_CR2","doi-asserted-by":"publisher","unstructured":"Sanchez LD, Bui A, Klesse LJ (2021) Targeted therapies for the neurofibromatoses. https:\/\/doi.org\/10.3390\/cancers13236032. Cancers 13.","DOI":"10.3390\/cancers13236032"},{"key":"4711_CR3","doi-asserted-by":"crossref","unstructured":"(2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 383:1290","DOI":"10.1056\/NEJMx200013"},{"key":"4711_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","volume":"23","author":"AE Armstrong","year":"2023","unstructured":"Armstrong AE, Belzberg AJ, Crawford JR et al (2023) Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer 23:553","journal-title":"BMC Cancer"},{"key":"4711_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR et al (2021) NF106: a neurofibromatosis clinical trials Consortium Phase II Trial of the MEK inhibitor Mirdametinib (PD-0325901) in adolescents and adults with NF1-Related plexiform neurofibromas. J Clin Oncol 39:797\u2013806","journal-title":"J Clin Oncol"},{"key":"4711_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian J, Chen JH, Chao SX et al (2023) Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial. Nat Med 29:458\u2013466","journal-title":"Nat Med"},{"key":"4711_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R et al (2024) Clinical and biomarker findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-negative breast Cancer: NeoPACT Phase 2 clinical trial. JAMA Oncol 10:227\u2013235","journal-title":"JAMA Oncol"},{"key":"4711_CR8","first-page":"55","volume":"12","author":"C Copley-Merriman","year":"2021","unstructured":"Copley-Merriman C, Yang X, Juniper M et al (2021) Natural history and Disease Burden of Neurofibromatosis Type 1 with plexiform neurofibromas: a systematic literature review. Adolesc Health Med Ther 12:55\u201366","journal-title":"Adolesc Health Med Ther"},{"key":"4711_CR9","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E et al (2021) Integrated analysis of multimodal single-cell data. Cell 184:3573\u20133587e29","journal-title":"Cell"},{"key":"4711_CR10","doi-asserted-by":"publisher","first-page":"9466","DOI":"10.1073\/pnas.1912139117","volume":"117","author":"J Wolbert","year":"2020","unstructured":"Wolbert J, Li X, Heming M et al (2020) Redefining the heterogeneity of peripheral nerve cells in health and autoimmunity. Proc Natl Acad Sci U S A 117:9466\u20139476","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4711_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-020-01103-4","volume":"9","author":"J-P Brosseau","year":"2021","unstructured":"Brosseau J-P, Sathe AA, Wang Y et al (2021) Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta Neuropathol Commun 9:11","journal-title":"Acta Neuropathol Commun"},{"key":"4711_CR12","doi-asserted-by":"publisher","first-page":"eabo5442","DOI":"10.1126\/sciadv.abo5442","volume":"8","author":"LMN Wu","year":"2022","unstructured":"Wu LMN, Zhang F, Rao R et al (2022) Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv 8:eabo5442","journal-title":"Sci Adv"},{"key":"4711_CR13","doi-asserted-by":"publisher","unstructured":"Ge L-L, Xing M-Y, Zhang H-B, Wang Z-C (2022) Neurofibroma Development in neurofibromatosis type 1: insights from Cellular Origin and Schwann Cell Lineage Development. https:\/\/doi.org\/10.3390\/cancers14184513. Cancers 14.","DOI":"10.3390\/cancers14184513"},{"key":"4711_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/glia.20776","volume":"56","author":"SL Carroll","year":"2008","unstructured":"Carroll SL, Ratner N (2008) How does the Schwann cell lineage form tumors in. NF1? Glia 56:1590\u20131605","journal-title":"NF1? Glia"},{"key":"4711_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.1068452","volume":"296","author":"Y Zhu","year":"2002","unstructured":"Zhu Y, Ghosh P, Charnay P et al (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920\u2013922","journal-title":"Science"},{"key":"4711_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13073-021-01001-x","volume":"13","author":"C Fustero-Torre","year":"2021","unstructured":"Fustero-Torre C, Jim\u00e9nez-Santos MJ, Garc\u00eda-Mart\u00edn S et al (2021) Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Med 13:187","journal-title":"Genome Med"},{"key":"4711_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM et al (2017) A Next Generation Connectivity Map: L1000 platform and the first 1,000,000 profiles. Cell 171:1437\u20131452e17","journal-title":"Cell"},{"key":"4711_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603\u2013607","journal-title":"Nature"},{"key":"4711_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, Nagari RT, Spangler RD et al (2020) Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer 1:235\u2013248","journal-title":"Nat Cancer"},{"key":"4711_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jid.2023.03.1688","volume":"144","author":"W-N Wang","year":"2024","unstructured":"Wang W-N, Koguchi-Yoshioka H, Nimura K et al (2024) Distinct transcriptional profiles in the different phenotypes of Neurofibroma from the same subject with neurofibromatosis 1. J Invest Dermatol 144:133\u2013141e4","journal-title":"J Invest Dermatol"},{"key":"4711_CR21","doi-asserted-by":"publisher","unstructured":"Kershner LJ, Choi K, Wu J et al (2022) Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight 7. https:\/\/doi.org\/10.1172\/jci.insight.154513","DOI":"10.1172\/jci.insight.154513"},{"key":"4711_CR22","first-page":"vdac005","volume":"4","author":"G Roman Souza","year":"2022","unstructured":"Roman Souza G, Abdalla A, Mahadevan D (2022) Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neurooncol Adv 4:vdac005","journal-title":"Neurooncol Adv"},{"key":"4711_CR23","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.esmoop.2021.100223","volume":"6","author":"I Solares","year":"2021","unstructured":"Solares I, Vi\u00f1al D, Morales-Conejo M et al (2021) Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open 6:100223","journal-title":"ESMO Open"},{"key":"4711_CR24","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E et al (2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 382:1430\u20131442","journal-title":"N Engl J Med"},{"key":"4711_CR25","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross AM, Dombi E, Wolters PL et al (2023) Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol 25:1883\u20131894","journal-title":"Neuro Oncol"},{"key":"4711_CR26","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","volume":"29","author":"DJ Chung","year":"2023","unstructured":"Chung DJ, Shah N, Wu J et al (2023) Randomized Phase II Trial of Dendritic Cell\/Myeloma Fusion Vaccine with Lenalidomide Maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401. Clin Cancer Res 29:4784\u20134796","journal-title":"Clin Cancer Res"},{"key":"4711_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7150\/ijms.78386","volume":"20","author":"Z Tian","year":"2023","unstructured":"Tian Z, You Y, Xiao M et al (2023) Inhibition of YAP sensitizes the Selumetinib treatment for neurofibromatosis type 1 related Plexiform Neurofibroma. Int J Med Sci 20:125\u2013135","journal-title":"Int J Med Sci"},{"key":"4711_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jid.2021.07.164","volume":"142","author":"W Wang","year":"2022","unstructured":"Wang W, Cui X-W, Gu Y-H et al (2022) Combined cyclin-dependent kinase inhibition overcomes MAPK\/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of neurofibromatosis type I. J Invest Dermatol 142:613\u2013623e7","journal-title":"J Invest Dermatol"},{"key":"4711_CR29","first-page":"i13","volume":"2","author":"S Li","year":"2020","unstructured":"Li S, Chen Z, Le LQ (2020) New insights into the neurofibroma tumor cells of origin. Neurooncol Adv 2:i13\u2013i22","journal-title":"Neurooncol Adv"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04711-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04711-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:16:22Z","timestamp":1721816182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04711-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4711"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04711-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}